EODData

MEMBERSHIP REGISTER LOG IN

FRA, 3O8: Omeros Corporation

03 Sep 2025
LAST:

3.526

CHANGE:
 0.15		OPEN:
3.620		HIGH:
3.620		ASK:
0.000		VOLUME:
1.1K
CHG(%):
4.13		PREV:
3.678		LOW:
3.482		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 253.6203.6203.4823.5261.1K
02 Sep 253.4703.7723.4703.6781.1K
01 Sep 253.4943.4943.4643.4721.1K
29 Aug 253.6483.6483.4883.5241.1K
28 Aug 253.6043.6883.5883.5881.1K
27 Aug 253.7163.7463.5963.5961.1K
26 Aug 253.6823.7463.6663.7461.1K
25 Aug 253.7043.7683.6863.7221.1K
22 Aug 253.8223.8263.6983.7301.1K
21 Aug 253.6283.8263.5483.8261.1K

COMPANY PROFILE

Name:Omeros Corporation
About:Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Sector:Healthcare
Industry:Biotechnology
Address:The Omeros Building, Seattle, WA, United States, 98119
Website:https://www.omeros.com
ISIN:US6821431029
LEI:549300CJWLXX2MXVVV71

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:3.56
MA10:3.64
MA20:3.60
MA50:3.24
MA100:3.63
MA200:6.03
STO9:15.25
STO14:13.92
RSI14:50.41
WPR14:-84.75
MTM14:-0.19
ROC14:-0.05
ATR:0.18
Week High:3.77
Week Low:3.46
Month High:3.86
Month Low:2.94
Year High:12.49
Year Low:2.47
Volatility:62.90